Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Exclusion Criteria

• •Specific anti-tumor treatment prior to 4 weeks;
• •more than 50% liver metastasis ;
• •Patient with other serious diseases or clinical conditions, including but not limited to uncontrolled active infection etc;
• •History of severe hypersensitivity reaction to any monoclonal antibody or chemistry;
• •Women who are pregnant or in the period of lactation;
• •Patients with an active, known or suspected autoimmune disease. Patients are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement;